Avexitide is expected to complete recruitment in Q1 2026 with topline Phase 3 LUCIDITY data anticipated in Q3 2026, and if approved, potential commercial launch in 2027. Beyond its lead asset, the company has received FDA Fast Track designation for AMX0114 in ALS treatment and is advancing AMX0035 in Wolfram syndrome. Amylyx leverages rare disease focus with FDA Breakthrough Therapy and Orphan Drug designations to address markets with significant unmet medical need.
Cyborg Score Rationale
Phase 2b avexitide data showed 64% reduction in composite hypoglycemic events (p=0.0031), supporting Phase 3 progression. Strong cash position and multi-program pipeline reduce binary risk, though pivotal trial outcomes in mid-2026 are critical inflection points.
Top Insights
Avexitide has FDA designations for breakthrough therapy and orphan status, reducing regulatory pathway risk and enabling potential expedited approval
Phase 3 LUCIDITY readout expected Q3 2026 represents transformative near-term catalyst with 2027 launch potential if successful
AMX0035 discontinuation in Progressive Supranuclear Palsy (2024) demonstrates portfolio discipline but reflects execution risk in CNS indications
Cash runway to 2028 supported by $344M cash position and recent $191M capital raise; burn rate improving with Q2 2025 loss of $41.4M vs Q2 2024 loss of $72.7M
Named Competitors
GLP-1 Receptor Antagonists — Competing in adjacent metabolic disease space; avexitide differentiated as antagonist
ALS/Neurodegenerative Programs — Competing for ALS indications; Amylyx AMX0114 in early Phase 1
Orphan Disease Focus — Competing in rare disease space with established commercial infrastructure
Recent Developments
(September 2025) Completed $175M public offering of 17.5M shares at $10/share, raising ~$191M net proceeds
(November 2025) Q3 2025 results: cash position of $344M; Phase 3 LUCIDITY recruitment on track for Q1 2026 completion
(December 2025) AMX0114 Phase 1 LUMINA safety/tolerability data presented; enrollment expansion to Canada and US planned
(January 2026) Nominated AMX0318, long-acting GLP-1 antagonist, as development candidate with IND targeted for 2027
Open the full interactive Amylyx Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.